Haemonetics Corporation Intrinsic Value Calculator – Haemonetics Corporation Posts Impressive Results in the Blood Play Market

☀️Trending News

Haemonetics Corporation ($NYSE:HAE) has posted impressive results in the blood processing and management market. Haemonetics has made significant progress in its efforts to develop innovative products, services, and processes that improve the safety and efficiency of blood processing and management. Haemonetics’ focus on quality, safety, and value has enabled it to achieve a strong financial performance. Over the past few years, Haemonetics’ sales have grown steadily, allowing it to expand its reach beyond the United States and into multiple international markets. Its customer base spans across multiple industries, such as healthcare, pharmaceuticals, biotechnology, and specialty medical products. The company’s product portfolio consists of point-of-care systems, mobile software solutions, and automated instruments. These products are designed to simplify the blood processing process and streamline operations.

In addition, Haemonetics offers a range of resources and services to help customers maximize the value of their products and services. Haemonetics has also made significant investments in research and development to ensure that they remain at the forefront of the industry. This focus on innovation has allowed them to develop a wide range of products that meet customer needs and expectations. As a result, the company has maintained a strong competitive advantage in the blood processing market. As the company continues to expand their global reach and product offerings, they will remain a leader in the industry for years to come.

Market Price

The stock opened at $83.2 and closed at $82.0, down by 0.6% from its last closing price of 82.4. Despite this small decline, investors have taken note of the company’s performance in the market and remain optimistic about the future of the blood play sector. The company has reported strong sales numbers and is looking to capitalize on the growing popularity of its products.

It has also invested in research and development to ensure that its products remain up to date with the latest developments in the market. HAEMONETICS CORPORATION’s stock has remained largely steady over the past few months, indicating that investors are confident in the company’s ability to deliver on its promises. With its steady performance and commitment to innovation, it looks poised to continue its successful run in the years ahead. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Haemonetics Corporation. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Haemonetics Corporation. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Haemonetics Corporation. More…

Key Ratios Snapshot

Some of the financial key ratios for Haemonetics Corporation are shown below. More…

Analysis – Haemonetics Corporation Intrinsic Value Calculator

GoodWhale has conducted a fundamental analysis of HAEMONETICS CORPORATION‘s financials and found that, according to our proprietary Valuation Line, the intrinsic value of HAEMONETICS CORPORATION stock is roughly $90.5. The current market price of HAEMONETICS CORPORATION stock is $82.0, which is a fair price but still undervalued by 9.4%. More…

Peers

The company has a wide range of products, including plasma collection systems, platelet and plasma pheresis systems, and whole blood collection systems. Haemonetics Corp. also provides services related to blood and plasma collection, such as plasma processing and storage, platelet and white blood cell processing, and whole blood processing. The company has a strong presence in the United States, Europe, Asia, and Australia. Merit Medical Systems Inc, Lagis Enterprise Co Ltd, StatSure Diagnostic Systems Inc are some of the major competitors of Haemonetics Corp.

– Merit Medical Systems Inc ($NASDAQ:MMSI)

Medtronic is a medical device company that develops and manufactures a wide range of products, from pacemakers to artificial hearts. The company has a market cap of $3.9 billion and a return on equity of 4.51%. Medtronic’s products are used by millions of people around the world, and the company is a leading provider of medical devices and services.

– Lagis Enterprise Co Ltd ($TPEX:6730)

Lagis Enterprise Co Ltd is a publicly traded company with a market capitalization of 1.02 billion as of 2022. The company has a return on equity of 12.12%. Lagis Enterprise Co Ltd is a diversified holding company that operates in a variety of industries, including construction, real estate, hospitality, and retail. The company has a strong presence in Taiwan and China, and its products and services are also available in North America, Europe, and Asia.

– StatSure Diagnostic Systems Inc ($OTCPK:SSUR)

StatSure Diagnostic Systems Inc is a company that manufactures and sells diagnostic products and services. The company has a market cap of 107.06k as of 2022 and a Return on Equity of 15.2%. The company’s products and services are used by healthcare professionals to diagnose and treat patients.

Summary

Haemonetics Corporation, a global healthcare company, is an attractive investment with solid, consistent performance. Haemonetics’ strategic investments in emerging markets and product development has helped to diversify its revenue streams and increase operating efficiency. Overall, investors can expect strong performance from this blood play.